GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » ROE % Adjusted to Book Value

Immunocore Holdings (Immunocore Holdings) ROE % Adjusted to Book Value : -3.78% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings ROE % Adjusted to Book Value?

Immunocore Holdings's ROE % for the quarter that ended in Mar. 2024 was -26.89%. Immunocore Holdings's PB Ratio for the quarter that ended in Mar. 2024 was 7.11. Immunocore Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -3.78%.


Immunocore Holdings ROE % Adjusted to Book Value Historical Data

The historical data trend for Immunocore Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings ROE % Adjusted to Book Value Chart

Immunocore Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - - -24.05 -3.00 -2.19

Immunocore Holdings Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.52 -2.49 0.37 -4.44 -3.78

Competitive Comparison of Immunocore Holdings's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Immunocore Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunocore Holdings's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's ROE % Adjusted to Book Value falls into.



Immunocore Holdings ROE % Adjusted to Book Value Calculation

Immunocore Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-15.91% / 7.28
=-2.19%

Immunocore Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-26.89% / 7.11
=-3.78%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunocore Holdings ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunocore Holdings (Immunocore Holdings) Business Description

Traded in Other Exchanges
Address
92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.